参考文献/References:
[1] 胡盛寿润霖刘力生等. 《中国心血管病报告2018》概要[J]. 中国循环杂志2019,34(3):209-220.
[2] Hansen CE,Qiu Y,McCarty OJT,et al. Platelet mechanotransduction[J]. Annu Rev Biomed Eng,2018,20:253-275.
[3] Zhang XF,Zhang W,Quach ME,et al. Force-regulated refolding of the mechanosensory domain in the platelet glycoprotein Ⅰb-Ⅸ complex[J]. Biophys J,2019,116(10):1960-1969.
[4] Ju L,Chen Y,Xue L,et al. Cooperative unfolding of distinctive mechanoreceptor domains transduces force into signals[J]. Elife,2016,5:e15447.
[5] Rayes J,Watson SP,Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2[J]. J Clin Invest,2019,129(1):12-23.
[6] Haining EJ,Cherpokova D,Wolf K,et al. CLEC-2 contributes to hemostasis independently of classical hemITAM signaling in mice[J]. Blood,2017,130(20):2224-2228.
[7] Gao J,Huang M,Lai J,et al. Kindlin supports platelet integrin αⅡbβ3 activation by interacting with paxillin[J]. J Cell Sci,2017,130(21):3764-3775.
[8] Li H,Deng Y,Sun K,et al. Structural basis of kindlin-mediated integrin recognition and activation[J]. Proc Natl Acad Sci U S A,2017,114(35):9349-9354.
[9] Haydari Z,Shams H,Jahed Z,et al. Kindlin assists talin to promote integrin activation[J]. Biophys J,2020,118(8):1977-1991.
[10] Stefanini L,Bergmeier W. RAP GTPases and platelet integrin signaling[J]. Platelets,2019,30(1):41-47.
[11] Bromberger T,Klapproth S,Rohwedder I,et al. Direct Rap1/Talin1 interaction regulates platelet and neutrophil integrin activity in mice[J]. Blood,2018,132(26):2754-2762.
[12] Gingras AR,Lagarrigue F,Cuevas MN,et al. Rap1 binding and a lipid-dependent helix in talin F1 domain promote integrin activation in tandem[J]. J Cell Biol,2019,218(6):1799-1809.
[13] Bromberger T,Zhu L,Klapproth S,et al. Rap1 and membrane lipids cooperatively recruit talin to trigger integrin activation[J]. J Cell Sci,2019,132(21):jcs235531.
[14] Raslan Z,Naseem KM. The control of blood platelets by cAMP signalling[J]. Biochem Soc Trans,2014,42(2):289-294.
[15] Laurent PA,Hechler B,Solinhac R,et al. Impact of PI3Kα(phosphoinositide 3-kinase alpha) inhibition on hemostasis and thrombosis[J]. Arterioscler Thromb Vasc Biol,2018,38(9):2041-2053.
[16] Laurent PA,Severin S,Hechler B,et al. Platelet PI3Kβ and GSK3 regulate thrombus stability at a high shear rate[J]. Blood,2015,125(5):881-888.
[17] Stefanini L,Paul DS,Robledo RF,et al. RASA3 is a critical inhibitor of RAP1-dependent platelet activation[J]. J Clin Invest,2015,125(4):1419-1432.
[18] Feghhi S,Tooley WW,Sniadecki NJ. Nonmuscle myosin ⅡA regulates platelet contractile forces through Rho kinase and myosin light-chain kinase[J]. J Biomech Eng,2016,138(10):1045061-1045064.
[19] Lu DH,Hsu CC,Huang SW,et al. ARHGEF10 knockout inhibits platelet aggregation and protects mice from thrombus formation[J]. J Thromb Haemost,2017,15(10):2053-2064.
[20] Qasim H,Karim ZA,Hernandez KR,et al. Arhgef1 plays a vital role in platelet function and thrombogenesis[J]. J Am Heart Assoc,2019,8(9):e011712.
[21] Jones S,Evans RJ,Mahaut-Smith MP. Ca2+ influx through P2X1 receptors amplifies P2Y1 receptor-evoked Ca2+ signaling and ADP-evoked platelet aggregation[J]. Mol Pharmacol,2014,86(3):243-251.
[22] Estevez B,Kim K,Delaney MK,et al. Signaling-mediated cooperativity between glycoprotein Ⅰb-Ⅸand protease-activated receptors in thrombin-induced platelet activation[J]. Blood,2016,127(5):626-636.
[23] Capra V,Mauri M,Guzzi F,et al. Impaired thromboxane receptor dimerization reduces signaling efficiency:A potential mechanism for reduced platelet function in vivo[J]. Biochem Pharmacol,2017,124:43-56.
[24] Lei X,Reheman A,Hou Y,et al. Anfibatide,a novel GPⅠb complex antagonist,inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis[J]. Thromb Haemost,2014,111(2):279-289.
[25] Franchi F,Rollini F,Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI[J]. Nat Rev Cardiol,2017,14(6):361-379.
[26] Dery JP,Mahaffey KW,Tricoci P,et al. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar[J]. Catheter Cardiovasc Interv,2016,88(2):163-173.
[27] Wong PC,Seiffert D,Bird JE,et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding[J]. Sci Transl Med,2017,9(371):eaaf5294.